Literature DB >> 16405510

Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease.

Paula A Desplats1, Kristi E Kass, Tim Gilmartin, Gregg D Stanwood, Elliott L Woodward, Steven R Head, J Gregor Sutcliffe, Elizabeth A Thomas.   

Abstract

We have identified and cataloged 54 genes that exhibit predominant expression in the striatum. Our hypothesis is that such mRNA molecules are likely to encode proteins that are preferentially associated with particular physiological processes intrinsic to striatal neurons, and therefore might contribute to the regional specificity of neurodegeneration observed in striatal disorders such as Huntington's disease (HD). Expression of these genes was measured simultaneously in the striatum of HD R6/1 transgenic mice using Affymetrix oligonucleotide arrays. We found a decrease in expression of 81% of striatum-enriched genes in HD transgenic mice. Changes in expression of genes associated with G-protein signaling and calcium homeostasis were highlighted. The most striking decrement was observed for a newly identified subunit of the sodium channel, beta 4, with dramatic decreases in expression beginning at 8 weeks of age. A subset of striatal genes was tested by real-time PCR in caudate samples from human HD patients. Similar alterations in expression were observed in human HD and the R6/1 model for the striatal genes tested. Expression of 15 of the striatum-enriched genes was measured in 6-hydroxydopamine-lesioned rats to determine their dependence on dopamine innervation. No changes in expression were observed for any of these genes. These findings demonstrate that mutant huntingtin protein causes selective deficits in the expression of mRNAs responsible for striatum-specific physiology and these may contribute to the regional specificity of degeneration observed in HD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16405510     DOI: 10.1111/j.1471-4159.2005.03588.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  61 in total

1.  Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity.

Authors:  Ana Saavedra; Albert Giralt; Laura Rué; Xavier Xifró; Jian Xu; Zaira Ortega; José J Lucas; Paul J Lombroso; Jordi Alberch; Esther Pérez-Navarro
Journal:  J Neurosci       Date:  2011-06-01       Impact factor: 6.167

2.  Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease.

Authors:  Tyisha Hathorn; Abigail Snyder-Keller; Anne Messer
Journal:  Neurobiol Dis       Date:  2010-08-22       Impact factor: 5.996

3.  In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons.

Authors:  Elizabeth A Thomas; Giovanni Coppola; Bin Tang; Alexandre Kuhn; SoongHo Kim; Daniel H Geschwind; Timothy B Brown; Ruth Luthi-Carter; Michelle E Ehrlich
Journal:  Hum Mol Genet       Date:  2010-12-20       Impact factor: 6.150

4.  Decreased Lin7b expression in layer 5 pyramidal neurons may contribute to impaired corticostriatal connectivity in huntington disease.

Authors:  Birgit Zucker; Jibrin A Kama; Alexandre Kuhn; Doris Thu; Lianna R Orlando; Anthone W Dunah; Ozgun Gokce; David M Taylor; Johann Lambeck; Bernd Friedrich; Katrin S Lindenberg; Richard L M Faull; Cornelius Weiller; Anne B Young; Ruth Luthi-Carter
Journal:  J Neuropathol Exp Neurol       Date:  2010-09       Impact factor: 3.685

5.  Huntington's disease brain-derived small RNAs recapitulate associated neuropathology in mice.

Authors:  Jordi Creus-Muncunill; Anna Guisado-Corcoll; Veronica Venturi; Lorena Pantano; Georgia Escaramís; Marta García de Herreros; Maria Solaguren-Beascoa; Ana Gámez-Valero; Cristina Navarrete; Mercè Masana; Franc Llorens; Daniela Diaz-Lucena; Esther Pérez-Navarro; Eulàlia Martí
Journal:  Acta Neuropathol       Date:  2021-02-06       Impact factor: 17.088

6.  Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.

Authors:  Haiqun Jia; Judit Pallos; Vincent Jacques; Alice Lau; Bin Tang; Andrew Cooper; Adeela Syed; Judith Purcell; Yi Chen; Shefali Sharma; Gavin R Sangrey; Shayna B Darnell; Heather Plasterer; Ghazaleh Sadri-Vakili; Joel M Gottesfeld; Leslie M Thompson; James R Rusche; J Lawrence Marsh; Elizabeth A Thomas
Journal:  Neurobiol Dis       Date:  2012-05       Impact factor: 5.996

7.  Egr-1 induces DARPP-32 expression in striatal medium spiny neurons via a conserved intragenic element.

Authors:  Serene Keilani; Samira Chandwani; Georgia Dolios; Alexey Bogush; Heike Beck; Antonis K Hatzopoulos; Gadiparthi N Rao; Elizabeth A Thomas; Rong Wang; Michelle E Ehrlich
Journal:  J Neurosci       Date:  2012-05-16       Impact factor: 6.167

8.  Functional roles for the striatal-enriched transcription factor, Bcl11b, in the control of striatal gene expression and transcriptional dysregulation in Huntington's disease.

Authors:  Paula A Desplats; James R Lambert; Elizabeth A Thomas
Journal:  Neurobiol Dis       Date:  2008-05-22       Impact factor: 5.996

9.  Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis.

Authors:  Kristina Becanovic; Mahmoud A Pouladi; Raymond S Lim; Alexandre Kuhn; Paul Pavlidis; Ruth Luthi-Carter; Michael R Hayden; Blair R Leavitt
Journal:  Hum Mol Genet       Date:  2010-01-20       Impact factor: 6.150

10.  The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice.

Authors:  Elizabeth A Thomas; Giovanni Coppola; Paula A Desplats; Bin Tang; Elisabetta Soragni; Ryan Burnett; Fuying Gao; Kelsey M Fitzgerald; Jenna F Borok; David Herman; Daniel H Geschwind; Joel M Gottesfeld
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.